KIRKLAND, Wash.--(Business Wire)--Cardiac Insight, Inc., a leading U.S. developer of wearable cardiac
medical devices and diagnostic software systems with proprietary
algorithms, announced today the company will showcase its innovative
solutions for the first time at Heart Rhythm Society’s 39
th
Annual Scientific Sessions. Heart Rhythm 2018 will be held May 9-11,
2018 in the Boston Convention and Exhibition Center (
https://www.hrssessions.org).
Cardiac Insight will present live interactive demonstrations of its
Cardea SOLO™, a wearable, wire-free 7-day ECG Sensor and PC-based,
in-office Analysis Software System for the detection of adult
arrhythmias, including atrial fibrillation (AFib), and Cardea 20/20
ECG™, a 12-lead test for identification of the risk of Sudden Cardiac
Arrest in young athletes, at the event’s main convention hall, Exhibit
1071.
Case studies will be presented that illustrate how Cardiac Insight’s
differentiated approach is helping clinicians achieve earlier diagnosis
of challenging cardiac arrhythmias such as atrial fibrillation in
adults, and life-threatening, but often clinically silent arrhythmias
and underlying cardiac disease in young athletes.
Heart Rhythm 2018 attendees are also invited to participate in Cardiac
Insight’s special book-signing event for HEART STORIES, a
collection of personal essays about patients and the great pioneers who
saved them, authored by renowned cardiologist, former President of the
Heart Rhythm Society and Cardiac Insight Scientific Advisory Board Chair
Robert G. Hauser, MD. Book signings will take place in the company Exhibit
1071 on:
-
May 9 – 5-6pm
-
May 10 – 10am-11am; 2-3pm
-
May 11 – 11am-12pm; 2:30-3:30pm
“Our differentiated frontline solutions, that address challenging
cardiac arrhythmia diagnoses, are rapidly gaining recognition by some of
the world’s top cardiologists and researchers,” said Brad Harlow, Chief
Executive Officer of Cardiac Insight, Inc. “Heart Rhythm 2018 will help
ensure more of the industry’s premier cardiologists,
electrophysiologists and cardiac researchers are aware of our
game-changing technology, and will also provide us the opportunity to
gain valuable market insights to best serve arrhythmia healthcare
professionals well into the future.”
The Cardea SOLO System leverages one of Cardiac Insight’s main
differentiators – its proprietary ECG Analysis Software that
incorporates advanced arrhythmia detection algorithms. Cardea SOLO
streamlines ambulatory patient diagnosis at the point of care, and
eliminates the need for costly and time-consuming outsourced ECG
scanning services.
Cardea SOLO is the ONLY in-office PC-based ECG Analysis Software cleared
by the U.S. Food and Drug Administration (FDA) to produce an automated
draft findings report without human intervention. The report is ready
for clinician review or edits in five minutes or less. Cardea SOLO
Software also provides clinicians access to and ownership of every
heartbeat of patient data for further analysis.
The Heart Rhythm Society’s 39th Annual Scientific Sessions convenes the
finest clinicians, scientists, researchers and innovators in the field
of cardiac pacing and electrophysiology. More than 800 of the world’s
most noted experts in cardiac rhythm management serve as faculty for
more than 240 educational sessions while more than 130 exhibitors
showcase innovative products and services.
Millions of adults across the United States and Europe suffer from
arrhythmia in its most common form, atrial fibrillation (AFib). Patients
with AFib face an estimated five-times higher risk of stroke and more
than double their risk of Sudden Cardiac Death. In young adult athletes,
Sudden Cardiac Arrest is the number one medical cause of death; it is
estimated that every 72 hours an athlete dies in the U.S. from cardiac
arrest.
About Cardiac Insight, Inc.
Cardiac Insight, Inc. (www.cardiacinsightinc.com)
is a leading U.S. developer of advanced body-worn digital health care
information systems through its proprietary software, algorithms and
devices. The company’s two flagship products are its wearable ECG Sensor
and Analysis Software System, Cardea SOLO™ (www.cardeasolo.com),
and Cardea 20/20 ECG™, the only 12-lead test that incorporates the
International Criteria for identification of the risk of Sudden Cardiac
Arrest in young athletes. Founded in 2008, Cardiac Insight is an
ISO-certified company and is based in Kirkland, Washington, USA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180503005945/en/
For Cardiac Insight, Inc.
Teresa Fausti, 425-503-5674
teresa@fausticommunications.com
